AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: The results revealed that the targets of GD-NAIs were mainly enriched in PI3K/AKT, MAPK, Endocrine resistance, Ras, FoxO, Th17 cell differentiation, JAK/STAT and TGF-β signaling pathways (Figure 5; Table S3), which are all potential therapeutic targets of CML.